Blood
Articles in this Issue
Pattern of infections and impact on immunocompetence of next generation B-cell depleting immunotherapies in non-Hodgkin's lymphomas: Results from a multicentre retrospective real- life cohort.
Abstract Introduction: Novel immunotherapies (including antiCD19 CAR-T cells, bispecific antiCD20/antiCD3 Monoclonal Antibodies (MoAbs), Ant...
Efficacy and safety results of TQB3909，a novel BCL-2 inhibitor, in combination with azacitidine for patients with myeloid malignancies
Abstract Background: Acute myeloid leukemia (AML) is the most common acute form of leukemia in adults and has an aggressive disease course....
Evaluation of serum TIE-2 levels in newly diagnosed and untreated multiple myeloma patients
Abstract Background: Multiple myeloma (MM) is an incurable hematologic malignancy characterized by the clonal proliferation of plasma cells...
A phase II Study of fedratinib and nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment – fraction Study / IKF051 / gsg-MPN-006
Abstract Introduction: Early clinical trials for patients with myelofibrosis (MF) are aimed to improve treatment using combinatorial therapi...
Vennetoclax combined with decitabine, cytarabine, aclacinomycin and granulocyte colony-stimulating factor as induction regimen achieved high response rate in newly diagnosed adverse risk Acute Myeloid Leukemia
Abstract Background With the identification of increasing molecular markers, acute myeloid leukemia (AML) patients in the adverse risk group...
Trial in progress: A phase 1b/2a study to evaluate mezigdomide in combination with elranatamab in patients with relapsed/refractory multiple myeloma
Abstract Background and Significance:Most patients with multiple myeloma (MM) will eventually experience relapse, resulting in poor prognosi...
Impact of autoimmune disease on outcomes after BCMA-directed CAR-T cell therapy for patients with multiple myeloma
Abstract Background: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are BCMA-directed CAR T-cell therapies effec...
A phase 2 dose confirmation trial of oral ASTX030, a combination of oral azacitidine with cedazuridine among patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
Abstract Background: Parenteral hypomethylating agents such as azacitidine (AZA) and decitabine are standard treatments...
Daratumumab for relapsed/refractory primary effusion lymphoma, plasmablastic lymphoma and multicentric castleman disease.
Abstract Background and Significance Primary effusion lymphoma (PEL), an aggressive B-cell non-Hodgkin lymphoma (NHL), and a plasmablastic f...
An integrated oral-gut microbiome and clinical feature model predicts myelosuppression risk after neoadjuvant chemoradiotherapy in colorectal cancer
Abstract Background Colorectal cancer (CRC) is a leading global malignancy, with neoadjuvant chemoradiotherapy (nCRT) as standard care for l...
Ferroportin Q248H mutation is associated with the less weight loss in persons with HIV-1
Abstract Ferroportin (FPN) disease is a genetically predisposed iron overload driven by over 30 mutations in the FPN gene that increase FPN...
CXCR5⁺PD-1⁻ circulating T follicular helper cells identify vaccine readiness in pediatric allogeneic hematopoietic cell transplantation
Abstract Background:
Children undergoing allogeneic hematopoietic cell transplantation (allo-HCT) are highly susceptible to vacci...
AML maturation stages associate with disease-permissive and immunosuppressive effects in newly diagnosed AML patients: An analysis at the single-cell level
Abstract Introduction: The clinical outcome of acute myeloid leukemia (AML) is determined by therapy resistance and relapse. AML-induced immu...
Long-term outcomes of allo-HSCT in SET::CAN-positive Hematological Malignancies: A 12-year single-center Study of 36 patients
Abstract Introduction The SET::CAN (SET::NUP214) fusion, occurring in 4-6% of T-cell acute lymphoblastic leukemia(T-ALL) cases,confers gluco...
Splenomegaly patterns and clinical impact in African children with sickle cell anemia on hydroxyurea treatment
Abstract Introduction. Splenomegaly is a challenging complication for children with sickle cell anemia (SCA) in sub-Saharan Africa, with lit...
Ixazomib combined with daratumumab-based regimens as first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma: A real-world historical database analysis from China
Abstract Background Emerging novel therapies have significantly improved survival in patients with multiple myeloma (MM)...
Real world outcomes of bispecific T-cell engagers in plasma cell leukemia
Abstract Background Patients (pts) with plasma cell leukemia (PCL) were excluded from key trials, so we assessed their outcomes with standar...
Low skeletal muscle mass and cancer cachexia among patients with multiple myeloma undergoing CAR-T cell therapy
Abstract Introduction: Chimeric Antigen Receptor T-cell therapy (CAR-T) has changed the treatment landscape of patients (pts) with relapsed...
Maternal outcomes in sickle cell trait patients hospitalized with preeclampsia and eclampsia
Abstract Introduction Preeclampsia and Eclampsia are progressive hypertensive disorders of pregnancy that begin after 20...
Multicenter Phase II trial of enasidenib as maintenance treatment following allogeneic stem cell transplantation in IDH2-mutated myeloid neoplasms – the IDH2-post-allo-trial (NCT04522895)
Abstract Introduction Allo-SCT is the recommend curative approach for the majority of fit pts with AML and MDS, but relapse is common and re...
Impact of prior venetoclax use on mortality in CLL patients treated with pirtobrutinib: A propensity-matched cohort study
Abstract Background Pirtobrutinib is a highly selective, non-covalent Bruton tyrosine kinase inhibitor (BTKi) approved for patients (pts) wi...
Inflammatory biomarkers in immune thrombotic thrombocytopenic purpura (iTTP): Focus on citrullinated H3 histone, tumor necrosis factor-alpha, and interleukin-6.
Abstract Introduction and aims: Immune Thrombotic Thrombocytopenic Purpura (iTTP) is a rare, life-threatening thrombotic microangiopathy cau...
CHN1 suppresses B-cell non-Hodgkin lymphoma progression via akt/mTOR pathway
Abstract Introduction B-cell non-Hodgkin lymphoma (B-NHL) is the most prevalent NHL subtype, exhibiting high heterogeneity. Chimerin 1 (CHN1...
Detection of Acute Myeloid Leukemia and related hematologic malignancies by machine learning using complete blood counts
Abstract Introduction The standard means of diagnosis for acute myeloid leukemia (AML) is through a bone marrow biopsy,...
Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8‑color flow cytometry panel reveals substantial differences among products kinetics and persistence
Abstract Background: Chimeric antigen receptor T cells (CAR-T) represent a groundbreaking therapy in hematologic malignancies. Currently app...